Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesEdgewise Therapeutics Inc

Edgewise Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
46.565 USD 1.52 ( 3.39%)
Last update at 2026-11-09T18:12:00Z
VOLUME
1041921
Market Cap
3643.98M

Momentum Score

…

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
44.58
Low
46.64
High
52 Week Price Range
12.15
Low
35.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for rare neuromuscular and muscle-wasting disorders. Its long-term growth drivers include successful progression of clinical programs, regulatory approvals and strategic partnerships to commercialize therapies, and it may benefit from significant unmet medical need in its target indications.

The most important investment risks are trial and regulatory failure, limited operating history with negligible product revenue, and the likely need for additional financing that could dilute shareholders.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
45.04
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-34.19%
Net Debt
-57.16M
ROCE
-31.95%
Diluted EPS TTM
-1.63

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -167.79M -133.81M -100.16M -19.41M -42.81M
Net income -167.79M -133.81M -100.16M -15.40M -42.14M
Selling general administrative 40.02M 31.87M 23.45M 5.47M 11.03M
Selling and marketing expenses - - 0.18M - -
Gross profit -2.27M -2.29M -1.73M - -
Reconciled depreciation 2.27M 2.29M 1.73M 0.54M 0.27M
Ebit -167.79M -158.83M -114.36M -22.62M -43.49M
Ebitda -165.53M -156.54M -112.62M -22.08M -43.22M
Depreciation and amortization 2.27M 2.29M 1.73M 0.54M 0.27M
Non operating income net other - - - 4.02M 0.40M
Operating income -191.41M -158.83M -114.36M -22.08M -43.22M
Other operating expenses 191.41M 158.83M 114.36M 22.08M 43.22M
Interest expense - - - 4.02M 0.27M
Interest income 23.61M 25.02M 14.19M 4.02M 0.40M
Net interest income 23.61M 25.02M 14.19M 4.02M 0.40M
Income tax expense - -0.00M - -4.02M -0.67M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 189.14M 158.83M 114.36M 22.08M 43.22M
Cost of revenue 2.27M 2.29M 1.73M - -
Total other income expense net 23.61M 25.02M 14.19M 2.66M 0.40M
Net income from continuing ops -167.79M -133.81M -100.16M -67.64M -42.81M
Net income applicable to common shares - - - -67.64M -42.81M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 552.60M 486.82M 340.04M 367.10M 285.23M
Other current assets 13.28M 5.31M 8.60M 5.05M 2.98M
Total liab 30.35M 27.60M 21.20M 20.39M 10.85M
Total stockholder equity 522.26M 459.22M 318.83M 346.72M 274.38M
Deferred long term liab - - - 0.25M -
Other current liab 20.35M 17.29M 11.77M 9.87M 6.68M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -546.37M -378.58M -244.76M -144.60M -76.96M
Other liab - - - - 0.33M
Other assets - - - 0.25M 0.55M
Cash 61.15M 41.67M 86.10M 351.95M 280.79M
Total current liabilities 27.37M 23.86M 16.77M 16.59M 10.52M
Net debt -57.16M -36.93M -80.68M -347.54M -280.79M
Short term debt 1.01M 1.00M 0.98M 0.61M -
Short long term debt total 3.99M 4.74M 5.41M 4.41M -
Other stockholder equity 1067.94M 837.36M 563.49M 492.67M 66.62M
Property plant equipment - - - 8.53M 0.91M
Total current assets 543.38M 475.48M 327.00M 351.95M 280.79M
Net tangible assets - - - 346.72M 274.38M
Short term investments 468.96M 428.50M 232.30M 329.95M 265.22M
Net receivables - - - 0.25M 0.55M
Accounts payable 6.01M 5.58M 4.03M 6.11M 3.84M
Accumulated other comprehensive income 0.68M 0.42M 0.10M -1.35M -0.51M
Common stock total equity - - - 0.01M 0.01M
Retained earnings total equity - - - -144.60M -76.96M
Non currrent assets other - 0.26M 0.35M 5.30M 3.53M
Non current assets total 9.22M 11.33M 13.04M 15.15M 4.44M
Capital lease obligations 3.99M 4.74M 5.41M 4.41M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -32.53M -184.66M 0.31M -70.58M -241.56M
Change to liabilities - - - 2.62M 7.02M
Total cashflows from investing activities -32.79M -184.66M 102.89M -70.58M -242.23M
Net borrowings - - - -0.25M -
Total cash from financing activities 196.09M 249.25M 53.17M 129.64M 186.38M
Change to operating activities - - - 4.04M 1.98M
Net income -167.79M -133.81M -100.16M -67.64M -42.81M
Change in cash 19.48M -44.43M 64.10M 6.43M -89.35M
Begin period cash flow 41.67M 86.10M 21.99M 15.57M 104.92M
End period cash flow 61.15M 41.67M 86.10M 21.99M 15.57M
Total cash from operating activities -143.82M -109.03M -91.95M -52.63M -33.51M
Issuance of capital stock 187.36M 239.15M -0.56M 129.16M 186.15M
Depreciation 2.27M 2.29M 1.73M 0.54M 0.27M
Other cashflows from investing activities -32.79M - - - -
Sale purchase of stock - - - 129.89M 186.38M
Other cashflows from financing activities 196.09M 10.11M 0.55M 0.47M 0.24M
Change to netincome - - - 10.92M 4.40M
Capital expenditures 0.26M 1.31M 5.75M 5.55M 0.67M
Cash flows other operating - - - 1.64M -2.39M
Cash and cash equivalents changes - - - 6.43M -89.35M
Change in working capital -5.37M 10.33M -1.56M 4.09M 4.63M
Stock based compensation 34.75M 24.71M 17.56M 10.92M 4.40M
Other non cash items 27.09M -12.54M -9.52M -0.54M -228.94M
Free cash flow -143.82M -110.34M -97.69M -58.18M -34.17M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
EWTX
Edgewise Therapeutics Inc		 1.52
3.39%		 46.56 - - - 6.98 -2.60
NVO
Novo Nordisk A/S		 1.03
2.56%		 41.34 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Edgewise Therapeutics Inc

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

1715 38th Street, Boulder, CO, United States, 80301

720 262 7002

https://edgewisetx.com

146

Name Title Year Born
Dr. Kevin Koch Ph.D. Pres, CEO & Director 1960
Dr. Badreddin Edris Ph.D. Co-Founder & Independent Director 1987
Dr. Behrad Derakhshan Ph.D. Chief Bus. Officer 1980
Dr. Joanne M. Donovan M.D., Ph.D. Chief Medical Officer 1957
Dr. Alan J. Russell Ph.D. Co-Founder, Chief Scientific Officer & Director 1970
Mr. R. Michael Carruthers Chief Financial Officer 1958
Mr. John R. Moore Gen. Counsel 1964
Dr. Peter A. Thompson FACP, M.D. Co-Founder & Independent Chairman 1960
Dr. Kevin Koch Ph.D. President, CEO & Director 1960
Dr. Badreddin Edris Ph.D. Co-Founder & Independent Director 1988

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…